Table 2 Risk factors associated with in-hospital detection of VRE in primary and secondary analysis in logistic regression analyses

LOS³ hospital, median (IQR)

15 (9–28)

7 (3, 12)

1.054 (1.028–1.081)

p ≤ 0.0001

LOS ICU³, median (IQR)

4 (1-10.5)

1 (0, 2)

1.114 (1.056–1.175)

p ≤ 0.0001

dialysis, n (%)

28 (24.1)

8 (6.9)

4.295 (1.864–9.897)

p ≤ 0.0005

3.309 (1.387–7.897)

p ≤ 0.0082

CVC³, n (%)

104 (89.7)

89 (76.7)

2.629 (1.259–5.492)

p ≤ 0.0167

1.663 (0.769–3.597)

p ≤ 0.3443

endoscopy, n (%)

55 (47.4)

34 (29.3)

1.802 (1.014–3.202)

p ≤ 0.0065

1.403 (0.761–2.585)

p ≤ 0.0821

sonography, n (%)

90 (77.6)

64 (55.2)

2.812 (1.591–4.971)

p ≤ 0.0009

2.169 (1.194–3.940)

p ≤ 0.0145

radiology (X-ray, CT, MRT), n (%)

102 (12.1)

78 (67.2)

3.549 (1.798–7.006)

p ≤ 0.0004

2.327 (1.136–4.769)

p ≤ 0.0623

antibiotics DOT, median (IQR)

16 (10–28)

4 (2, 11.5)

1.082 (1.052–1.112)

p ≤ 0.0001

1.069 (1.037–1.102)

p ≤ 0.0001

mean (IQR)

OR (95% CI)

p-value

P/T³ DOT

4.7 (0-7.5)

2.2 (0–2)

1.139 (1.067–1.216)

0.0001

1.116 (1.043–1.195)

0.0006

 A/S³ DOT

0.7 (0–0)

0.2 (0–0)

1.131(0.962–1.329)

0.1465

1.132 (0.945–1.356)

0.2069

meropenem DOT

3.9 (0-7.5)

0.8 (0–0)

1.198 (1.103–1.301)

0.0001

1.154 (1.058–1.258)

0.0005

imipenem DOT

0.3 (0–0)

0.3 (0–0)

1.013 (0.879–1.169)

0,6406

0.940 (0.810–1.093)

0.4870

CEPH³ 2nd gen DOT

0.8 (0–1)

1.1 (0–1)

0.926 (0.798–1.074)

0.0047

0.953 (0.822–1.104)

0.4427

CEPH³ 3rd gen DOT

0.7 (0–0)

0.4 (0–0)

1.067 (0.923–1.233)

0.1793

1.069 (0.921–1.241)

0.3129

ciprofloxacin DOT

2.1 (0–2)

0.7 (0–0)

1.147 (1.039–1.268)

0.0022

1.114 (1.002–1.238)

0.0502

levofloxacin DOT

0.2 (0–0)

0.2 (0–0)

1.040 (0.813–1.329)

0,8359

0.931 (0.697–1.245)

0.6474

metronidazole DOT

2.1 (0–3)

1.6 (0-1.5)

1.052(0.967–1.144)

0.5788

1.063 (0.975–1.160)

0.1267

vancomycin DOT

2.7 (0–3)

0.5 (0–0)

1.215(1.097–1.346)

0.0001

1.150(1.036–1.276)

0.0031

macrolids DOT

0.9(0–0)

0.3(0–0)

1.234(1.031–1.476)

0.0099

1.152(0.957–1.387)

0.0872

tetracyclins DOT

0.1(0–0)

0 (0–0)

1.121 (0.769–1.635)

1.0000

1.058(0.723–1.547)

0.7044

aminoglycosides DOT

0.1 (0–0)

0 (0–0)

nd⁴

0.2500

nd⁴

0.5270

linezolid DOT

0.3 (0–0)

0.3 (0–0)

1.010 (0.881–1.158)

0.9063

0.980(0.848–1.132)

0.8598

rifampicin DOT

0.1(0–0)

0.2 (0–0)

0.951 (0.792–1.141)

1.0000

0.912 (0.764–1.089)

0.3286

nitrofurantoin DOT

0 (0–0)

0 (0–0)

nd⁴

1.0000

nd⁴

0.1897

T/S³ DOT

0.2 (0–0)

0.1 (0–0)

0.981(0.848–1.135)

0.2813

0.919 (0.783–1.079)

0.3385

clindamycin DOT

0.1 (0–0)

0.3 (0–0)

1.107 (0.863–1.420)

0.3672

1.097 (0.844–1.427)

0.4649